SC
KNSA icon

Stempoint Capital’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Stempoint Capital’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.4M Buy
+209,234
New +$10.9M 2.3% 11
2024
Q1 		– Sell
-183,102
Closed -$3.21M – 80
2023
Q4 		$3.21M Buy
+183,102
New +$3.01M 0.86% 40

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Stempoint Capital's KNSA Position: Q2 2026 in Review

Stempoint Capital opened a new position in Kiniksa Pharmaceuticals (KNSA) in Q2 2026: 209,234 shares worth $13.4M. The stake represents 2.3% of the portfolio and ranks #11 among its holdings. This is a return to the name: Stempoint Capital previously reported a position in KNSA as recently as Q4 2023.

Stempoint Capital first reported a position in KNSA in Q4 2023 and has held it in 2 quarters since. 267 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Stempoint Capital held 209,234 shares of Kiniksa Pharmaceuticals worth $13.4M as of Q2 2026.
  • Kiniksa Pharmaceuticals was a new Stempoint Capital position in Q2 2026.
  • Kiniksa Pharmaceuticals made up 2.3% of Stempoint Capital's portfolio in Q2 2026, its #11 holding.
  • Stempoint Capital first reported a position in Kiniksa Pharmaceuticals in Q4 2023 and has held it in 2 quarters since.
  • 267 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.